<?xml version='1.0' encoding='utf-8'?>
<document id="21544077"><sentence text="Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects."><entity charOffset="37-50" id="DDI-PubMed.21544077.s1.e0" text="pyrimethamine" /><entity charOffset="80-89" id="DDI-PubMed.21544077.s1.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.21544077.s1.e0" e2="DDI-PubMed.21544077.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21544077.s1.e0" e2="DDI-PubMed.21544077.s1.e1" /></sentence><sentence text="A microdose study of metformin was conducted to investigate the predictability of drug-drug interactions at the therapeutic dose (ThD)"><entity charOffset="21-30" id="DDI-PubMed.21544077.s2.e0" text="metformin" /></sentence><sentence text=" Healthy subjects received a microdose (100 Âµg) or ThD (250 mg) of metformin orally, with or without a potent and competitive multidrug and toxin extrusion (MATE) inhibitor, pyrimethamine (50 mg, p"><entity charOffset="67-76" id="DDI-PubMed.21544077.s3.e0" text="metformin" /><entity charOffset="174-187" id="DDI-PubMed.21544077.s3.e1" text="pyrimethamine" /><pair ddi="false" e1="DDI-PubMed.21544077.s3.e0" e2="DDI-PubMed.21544077.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21544077.s3.e0" e2="DDI-PubMed.21544077.s3.e1" /></sentence><sentence text="o" /><sentence text="), in a crossover fashion" /><sentence text=" Pyrimethamine significantly reduced the renal clearance of metformin by 23 and 35% at the microdose and ThD, respectively"><entity charOffset="1-14" id="DDI-PubMed.21544077.s6.e0" text="Pyrimethamine" /><entity charOffset="60-69" id="DDI-PubMed.21544077.s6.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.21544077.s6.e0" e2="DDI-PubMed.21544077.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21544077.s6.e0" e2="DDI-PubMed.21544077.s6.e1" /></sentence><sentence text=" At ThD, but not at microdose, it caused significant increases in the maximum concentration (C(max)) and area under the plasma concentration-time curve (AUC) of metformin (142 and 139% of control values, respectively)"><entity charOffset="161-170" id="DDI-PubMed.21544077.s7.e0" text="metformin" /></sentence><sentence text=" Human canalicular membrane vesicles showed pyrimethamine-inhibitable metformin uptake"><entity charOffset="44-57" id="DDI-PubMed.21544077.s8.e0" text="pyrimethamine" /><entity charOffset="70-79" id="DDI-PubMed.21544077.s8.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.21544077.s8.e0" e2="DDI-PubMed.21544077.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21544077.s8.e0" e2="DDI-PubMed.21544077.s8.e1" /></sentence><sentence text=" Pyrimethamine did not affect plasma lactate/pyruvate after ThD of metformin but significantly reduced the renal clearance of creatinine, thereby causing elevation of plasma creatinine level"><entity charOffset="1-14" id="DDI-PubMed.21544077.s9.e0" text="Pyrimethamine" /><entity charOffset="37-44" id="DDI-PubMed.21544077.s9.e1" text="lactate" /><entity charOffset="45-53" id="DDI-PubMed.21544077.s9.e2" text="pyruvate" /><entity charOffset="67-76" id="DDI-PubMed.21544077.s9.e3" text="metformin" /><entity charOffset="126-136" id="DDI-PubMed.21544077.s9.e4" text="creatinine" /><entity charOffset="174-184" id="DDI-PubMed.21544077.s9.e5" text="creatinine" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e0" e2="DDI-PubMed.21544077.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e0" e2="DDI-PubMed.21544077.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e0" e2="DDI-PubMed.21544077.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e0" e2="DDI-PubMed.21544077.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e0" e2="DDI-PubMed.21544077.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e0" e2="DDI-PubMed.21544077.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e1" e2="DDI-PubMed.21544077.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e1" e2="DDI-PubMed.21544077.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e1" e2="DDI-PubMed.21544077.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e1" e2="DDI-PubMed.21544077.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e1" e2="DDI-PubMed.21544077.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e2" e2="DDI-PubMed.21544077.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e2" e2="DDI-PubMed.21544077.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e2" e2="DDI-PubMed.21544077.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e2" e2="DDI-PubMed.21544077.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e3" e2="DDI-PubMed.21544077.s9.e3" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e3" e2="DDI-PubMed.21544077.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e3" e2="DDI-PubMed.21544077.s9.e5" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e4" e2="DDI-PubMed.21544077.s9.e4" /><pair ddi="false" e1="DDI-PubMed.21544077.s9.e4" e2="DDI-PubMed.21544077.s9.e5" /></sentence><sentence text=" This microdose study quantitatively predicted a drug-drug interaction involving the renal clearance of metformin at ThD by pyrimethamine"><entity charOffset="104-113" id="DDI-PubMed.21544077.s10.e0" text="metformin" /><entity charOffset="124-137" id="DDI-PubMed.21544077.s10.e1" text="pyrimethamine" /><pair ddi="false" e1="DDI-PubMed.21544077.s10.e0" e2="DDI-PubMed.21544077.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21544077.s10.e0" e2="DDI-PubMed.21544077.s10.e1" /></sentence><sentence text=" Pyrimethamine is a useful in vivo inhibitor of MATE proteins"><entity charOffset="1-14" id="DDI-PubMed.21544077.s11.e0" text="Pyrimethamine" /></sentence><sentence text="" /></document>